Unlocking disease insights to facilitate drug development: Pharmaceutical industry-academia collaborations in inflammation and immunology

被引：0

作者：

Peeva, Elena ^{[1
]}

Guttman-Yassky, Emma ^{[2
,3
]}

Yamaguchi, Yuji ^{[4
]}

Berman, Brian ^{[5
]}

Oemar, Barry ^{[1
]}

Ramakrishna, Jyoti ^{[1
]}

Fasano, Alessio ^{[6
]}

Evans-Molina, Carmella ^{[7
,8
]}

Chu, Myron ^{[4
]}

Ungar, Benjamin ^{[2
,3
]}

Gulko, Percio S. ^{[9
]}

Padilla, Maria ^{[10
]}

Weiss, Roberta ^{[4
]}

Khosroshahi, Arezou ^{[11
]}

Brunner, Patrick M. ^{[2
,3
]}

Meariman, Marguerite ^{[2
,3
]}

Vincent, Michael S. ^{[1
]}

Dolsten, Mikael ^{[12
]}

机构：

[1] Pfizer, Inflammat & Immunol Res Unit, Cambridge, MA 02139 USA

[2] Icahn Sch Med Mt Sinai, Dept Dermatol, Lab Inflammatory Skin Dis, New York, NY USA

[3] Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, New York, NY USA

[4] Pfizer, Inflammat & Immunol Res Unit, Collegeville, PA USA

[5] Univ Miami, Dept Dermatol & Cutaneous Surg, Miami, FL USA

[6] Harvard Med Sch, Massachusetts Gen Hosp Children, Dept Pediat, Div Pediat Gastroenterol & Nutr, Boston, MA USA

[7] Indiana Univ Sch Med, Ctr Diabet & Metab Dis, Dept Pediat, Indianapolis, IN USA

[8] Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Dept Pediat, Indianapolis, IN USA

[9] Icahn Sch Med Mt Sinai, Dept Med, Div Rheumatol, New York, NY USA

[10] Icahn Sch Med Mt Sinai, Dept Med, Div Pulm Crit Care & Sleep Med, New York, NY USA

[11] Emory Univ, Sch Med, Dept Med, Div Rheumatol, Atlanta, GA USA

[12] Pfizer, New York, NY USA

来源：

DRUG DISCOVERY TODAY | 2025年 / 30卷 / 03期

关键词：

academia; autoimmune; collaboration; drug development; immunology; inflammation; pharmaceutical industry; ALOPECIA-AREATA; OPEN INNOVATION; CELIAC-DISEASE; DOUBLE-BLIND; EFFICACY; SAFETY; RITLECITINIB; BREPOCITINIB; ANTIBODIES; MANAGEMENT;

D O I：

10.1016/j.drudis.2025.104317

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Evolving research landscapes warrant updates development strategy. Collaborations between ceutical industry and academic institutions are crucial accelerating drug development, leveraging individual expertise in clinical trial conduct and pathophysi investigations. This review highlights key collab in drug pharmaological orations between Pfizer and academic institutions in inflammation and immunology research, including dermatology, gastroenterology, rheumatology, and autoimmunity. These collaborations harness enhance the development of innovative disease models, large clinical databases, registries, and novel clinical trial designs, and open new avenues in disease management to improve patient outcomes.

引用

页数：13

共 8 条

[1] Consideration on Industry-Academia Partnering in Drug Discovery Development: Based on a Questionnaire Survey of Pharmaceutical Companies and Academia
Iida, Kaori
Yano, Takahiko
Ikemori, Megumi
Ishida, Tomoki
Nishimura, Norihiro
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2021, 141 (06): : 877 - 886
[2] Pharmaceutical Industry in Pediatric Drug Development: Partners and Collaborators With Academia and the FDA
Mulberg, Andrew E.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2008, 47 (05): : 711 - 713
[3] Fostering collaborations across academia, industry, and government to develop biomarkers for decision-making in drug development
Wong, Dean F.
Csernansky, John
Waterhouse, Rikki
Burns, Don
Brady, Linda
Merchant, Kalpana
Lyketsos, Constantine
NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S12 - S12
[4] Barriers to Alzheimer disease drug discovery and drug development in the pharmaceutical industry
Anand, R
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2002, 16 : S33 - S39
[5] Designing greener active pharmaceutical ingredients: Insights from pharmaceutical industry into drug discovery and development
Puhlmann, Neele
Vidaurre, Rodrigo
Kuemmerer, Klaus
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 192
[6] Drug Development for Inflammatory Bowel Disease: Interaction Among Academia, Industry and Regulatory Authorities
Danese, Silvio
Vermeire, Severine
JOURNAL OF CROHNS & COLITIS, 2016, 10 : S541 - S541
[7] Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships: Insights from Roche's Endocannabinoid System Projects
Aebi, Johannes
Atz, Kenneth
Ametamey, Simon M.
Benz, Jorg
Blaising, Julie
Butini, Stefania
Campiani, Giuseppe
Carreira, Erick M.
Collin, Ludovic
de Lago, Eva
Gazzi, Thais
Gertsch, Jurg
Gobbi, Luca
Guba, Wolfgang
Fernandez-Ruiz, Javier
Fingerle, Jurgen
Haider, Ahmed
He, Yingfang
Heitman, Laura H.
Honer, Michael
Hunziker, Daniel
Kuhn, Bernd
Maccarrone, Mauro
Marki, Hans Peter
Martin, Rainer E.
Mohr, Peter
Mu, Linjing
Nazare, Marc
Nippa, David F.
Oddi, Sergio
O'Hara, Fionn
Pacher, Pal
Romero, Julian
Rover, Stephan
Rufer, Arne C.
Schibli, Roger
Schneider, Gisbert
Stepan, Antonia F.
Sykes, David A.
Ullmer, Christoph
van der Stelt, Mario
Veprintsev, Dmitry B.
Wittwer, Matthias B.
Grether, Uwe
CHIMIA, 2024, 78 (7-8) : 499 - 512
[8] Setbacks and promises for drugs against Alzheimer's disease As pharmaceutical companies are retreating from drug development for Alzheimer's, new approaches are being tested in academia and biotech companies
Rinaldi, Andrea
EMBO REPORTS, 2018, 19 (09)

← 1 →